Collectively, our results show that KDM2B inhibits the lytic cycle of KSHV following de novo infection mainly by binding to the RTA promoter as early as 8 hpi and reducing the level of specific activating histone marks on it at 24 hpi. This evidence concerns the gene KDM2B and infection.